Sorafenib for the treatment of advanced hepatocellular carcinoma

National Institute for Health and Clinical Excellence
Record ID 32011000078
English
Authors' recommendations: Sorafenib is not recommended for the treatment of advanced hepatocellular carcinoma in patients for whom surgical or locoregional therapies have failed or are not suitable.1.2 People currently receiving sorafenib for the treatment of advanced hepatocellular carcinoma should have the option to continue treatment until they and their clinician consider it appropriate to stop.
Details
Project Status: Completed
Year Published: 2010
URL for published report: http://www.nice.org.uk/TA189
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Antineoplastic Agents
  • Benzenesulfonates
  • Carcinoma, Hepatocellular
  • Pyridines
Contact
Organisation Name: National Institute for Health and Care Excellence
Contact Address: Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.